RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sumitomo Pharma Co Stock

Sumitomo Pharma Co Stocks 2024

Sumitomo Pharma Co Stocks

397.29 M

Ticker

4506.T

ISIN

JP3495000006

WKN

858257

In 2024, Sumitomo Pharma Co had 397.29 M outstanding stocks, a -0% change from the 397.29 M stocks in the previous year.

The Sumitomo Pharma Co Stocks history

YEARNUMBER OF STOCKS (undefined JPY)
2027e397.29
2026e397.29
2025e397.29
2024397.29
2023397.29
2022397.3
2021397.29
2020397.3
2019397.3
2018397.3
2017397.3
2016397.3
2015397.31
2014397
2013397
2012397
2011397
2010397
2009397
2008397
2007398
2006281
2005165

Sumitomo Pharma Co shares outstanding

The number of shares was Sumitomo Pharma Co in 2023 — This indicates how many shares 397.292 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sumitomo Pharma Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sumitomo Pharma Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sumitomo Pharma Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sumitomo Pharma Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sumitomo Pharma Co Aktienanalyse

What does Sumitomo Pharma Co do?

Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sumitomo Pharma Co's Shares Outstanding

Sumitomo Pharma Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sumitomo Pharma Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sumitomo Pharma Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sumitomo Pharma Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sumitomo Pharma Co stock

How many stocks are there of Sumitomo Pharma Co?

The current number of stocks of Sumitomo Pharma Co is 397.29 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sumitomo Pharma Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sumitomo Pharma Co evolved in recent years?

The number of shares of Sumitomo Pharma Co has increased by -0% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sumitomo Pharma Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sumitomo Pharma Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sumitomo Pharma Co pay?

Over the past 12 months, Sumitomo Pharma Co paid a dividend of 14 JPY . This corresponds to a dividend yield of about 2.43 %. For the coming 12 months, Sumitomo Pharma Co is expected to pay a dividend of 14 JPY.

What is the dividend yield of Sumitomo Pharma Co?

The current dividend yield of Sumitomo Pharma Co is 2.43 %.

When does Sumitomo Pharma Co pay dividends?

Sumitomo Pharma Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Sumitomo Pharma Co?

Sumitomo Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Sumitomo Pharma Co?

For the upcoming 12 months, dividends amounting to 14 JPY are expected. This corresponds to a dividend yield of 2.43 %.

In which sector is Sumitomo Pharma Co located?

Sumitomo Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sumitomo Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sumitomo Pharma Co from 6/1/2023 amounting to 7 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2023.

When did Sumitomo Pharma Co pay the last dividend?

The last dividend was paid out on 6/1/2023.

What was the dividend of Sumitomo Pharma Co in the year 2023?

In the year 2023, Sumitomo Pharma Co distributed 28 JPY as dividends.

In which currency does Sumitomo Pharma Co pay out the dividend?

The dividends of Sumitomo Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sumitomo Pharma Co

Our stock analysis for Sumitomo Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.